Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
101.18
-0.25 (-0.25%)
Streaming Delayed Price
Updated: 9:42 AM EST, Nov 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
294,969
Open
101.55
Bid (Size)
101.17 (1)
Ask (Size)
101.19 (1)
Prev. Close
101.43
Today's Range
101.11 - 101.62
52wk Range
59.77 - 105.69
Shares Outstanding
N/A
Dividend Yield
1.75%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
Today 5:50 EST
Real-world data showed some real-world advantages for Ozempic's top rival.
Via
The Motley Fool
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
November 28, 2023
The study examined health care records for more than 41,000 people.
Via
Investor's Business Daily
Performance
YTD
+47.75%
+47.75%
1 Month
+4.96%
+4.96%
3 Month
+6.30%
+6.30%
6 Month
+24.51%
+24.51%
1 Year
+66.92%
+66.92%
More News
Read More
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
November 28, 2023
Via
Benzinga
Only Have $100? 3 No-Brainer Stocks to Buy Right Now
November 28, 2023
Via
InvestorPlace
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
November 27, 2023
Via
Benzinga
BellRing Brands gets pumped on the Ozempic weight-loss trend
November 27, 2023
Via
MarketBeat
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
November 24, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
November 22, 2023
Via
Benzinga
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
November 26, 2023
Via
The Motley Fool
Google Leads Five S&P 500 Stocks Near Buy Points
November 25, 2023
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Could Ozempic Harm These 3 Medical Device Stocks?
November 25, 2023
Via
The Motley Fool
Novo Nordisk's Wegovy Eyes Asian Market Debut Despite Supply Crunch
November 24, 2023
Via
Benzinga
7 Stocks Set to Capitalize on the Coming Year-End Rally
November 24, 2023
Via
InvestorPlace
Peering Into Novo Nordisk's Recent Short Interest
November 22, 2023
Via
Benzinga
This Is What Whales Are Betting On Novo Nordisk
November 20, 2023
Via
Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Technical Analysis observations.
November 20, 2023
Via
Chartmill
$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years
November 23, 2023
Via
The Motley Fool
Emmanuel Macron To Unveil Novo Nordisk Record $2.3B Investment In France's Health Sector
November 23, 2023
Via
Benzinga
3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape
November 22, 2023
Via
InvestorPlace
Ozempic's Surging Demand Has Novo Nordisk Restricting It In Europe, Plus An Older Generation Diabetes Drug: What's Next?
November 21, 2023
Via
Benzinga
3 Consumer Goods Stocks That Will Define the Next Decade
November 21, 2023
Via
InvestorPlace
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
November 21, 2023
Via
Benzinga
Topics
ETFs
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
November 21, 2023
Via
Chartmill
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
November 20, 2023
Via
The Motley Fool
3 Stock-Split Stocks Billionaires Are Buying Hand Over Fist
November 20, 2023
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.